Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? - a pharmacoeconomic study. (2024). Headache Medicine, 15(3), 170-174. https://doi.org/10.48208/HeadacheMed.2024.34